Apeloa Pharmaceutical Co Ltd Total Assets
Apeloa Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Apeloa Pharmaceutical Co Ltd (000739) holds total assets worth CN¥12.25 Billion CNY (≈ $1.79 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 000739 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Apeloa Pharmaceutical Co Ltd (1994–2025)
Total assets of Apeloa Pharmaceutical Co Ltd from 1994 to 2025. This chart illustrates how Apeloa Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See latest Apeloa Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Apeloa Pharmaceutical Co Ltd - Asset Composition Analysis
Apeloa Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Apeloa Pharmaceutical Co Ltd total assets breakdown as of December 2025. Apeloa Pharmaceutical Co Ltd's total assets of CN¥12.25 Billion consist of 64.0% current assets and 36.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 30.7% |
| Accounts Receivable | CN¥2.36 Billion | 19.2% |
| Inventory | CN¥1.60 Billion | 13.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥348.95 Million | 2.8% |
| Goodwill | CN¥20.31 Million | 0.2% |
Asset Composition Trend (1994–2025)
This chart illustrates how Apeloa Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 000739 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apeloa Pharmaceutical Co Ltd's current assets represent 64.0% of total assets in 2025, an increase from 48.5% in 1994.
- Cash Position: Cash and equivalents constituted 30.7% of total assets in 2025, up from 4.2% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 19.2% of total assets.
Apeloa Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Apeloa Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Apeloa Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.55 | 1.51 | 1.62 |
| Quick Ratio | 1.28 | 1.20 | 1.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.81 Billion | CN¥2.76 Billion | CN¥2.17 Billion |
Apeloa Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Apeloa Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.96 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -3.2% |
| Total Assets | CN¥12.32 Billion |
| Market Capitalization | $3.66 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Apeloa Pharmaceutical Co Ltd's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Apeloa Pharmaceutical Co Ltd's assets decreased by 3.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Apeloa Pharmaceutical Co Ltd (1994–2025)
The table below shows the annual total assets of Apeloa Pharmaceutical Co Ltd from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥12.32 Billion ≈ $1.80 Billion |
-3.23% |
| 2024-12-31 | CN¥12.73 Billion ≈ $1.86 Billion |
-0.30% |
| 2023-12-31 | CN¥12.77 Billion ≈ $1.87 Billion |
+6.21% |
| 2022-12-31 | CN¥12.02 Billion ≈ $1.76 Billion |
+32.91% |
| 2021-12-31 | CN¥9.04 Billion ≈ $1.32 Billion |
+20.68% |
| 2020-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
+14.91% |
| 2019-12-31 | CN¥6.52 Billion ≈ $954.46 Million |
+13.40% |
| 2018-12-31 | CN¥5.75 Billion ≈ $841.66 Million |
+1.07% |
| 2017-12-31 | CN¥5.69 Billion ≈ $832.79 Million |
+1.28% |
| 2016-12-31 | CN¥5.62 Billion ≈ $822.23 Million |
+4.15% |
| 2015-12-31 | CN¥5.39 Billion ≈ $789.45 Million |
+6.58% |
| 2014-12-31 | CN¥5.06 Billion ≈ $740.70 Million |
+8.57% |
| 2013-12-31 | CN¥4.66 Billion ≈ $682.23 Million |
+13.51% |
| 2012-12-31 | CN¥4.11 Billion ≈ $601.02 Million |
+13.25% |
| 2011-12-31 | CN¥3.63 Billion ≈ $530.70 Million |
+96.61% |
| 2010-12-31 | CN¥1.84 Billion ≈ $269.92 Million |
+5.42% |
| 2009-12-31 | CN¥1.75 Billion ≈ $256.03 Million |
+0.49% |
| 2008-12-31 | CN¥1.74 Billion ≈ $254.78 Million |
+7.87% |
| 2007-12-31 | CN¥1.61 Billion ≈ $236.20 Million |
+27.63% |
| 2006-12-31 | CN¥1.26 Billion ≈ $185.07 Million |
+10.47% |
| 2005-12-31 | CN¥1.14 Billion ≈ $167.53 Million |
+2.73% |
| 2004-12-31 | CN¥1.11 Billion ≈ $163.08 Million |
+29.13% |
| 2003-12-31 | CN¥863.07 Million ≈ $126.29 Million |
+25.21% |
| 2002-12-31 | CN¥689.28 Million ≈ $100.86 Million |
+17.35% |
| 2001-12-31 | CN¥587.38 Million ≈ $85.95 Million |
+29.95% |
| 2000-12-31 | CN¥452.01 Million ≈ $66.14 Million |
-13.13% |
| 1999-12-31 | CN¥520.33 Million ≈ $76.14 Million |
+14.74% |
| 1998-12-31 | CN¥453.48 Million ≈ $66.36 Million |
+15.47% |
| 1997-12-31 | CN¥392.71 Million ≈ $57.47 Million |
+138.92% |
| 1996-12-31 | CN¥164.37 Million ≈ $24.05 Million |
+12.36% |
| 1995-12-31 | CN¥146.29 Million ≈ $21.41 Million |
+3.38% |
| 1994-12-31 | CN¥141.51 Million ≈ $20.71 Million |
-- |
About Apeloa Pharmaceutical Co Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&… Read more